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Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A 
Case–Control Study 
Abstract 
Background: Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory 
pain or intolerable opioid adverse effects (AEs). A unique ME AE is its corrected QT (QTc) interval 
prolongation risk, but most evidence exists in methadone maintenance therapy patients. 
Objective: Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and 
other medications known to prolong the QTc interval and develop a risk stratification tool. 
Design: We performed a case–control study of adult inpatients receiving ME for pain management. 
Settings/Subjects: Adult inpatients receiving ME with a QTc >470 msec (males) and >480 msec (females) 
were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients who did not 
have a prolonged QTc interval. QTc prolongation risk factors were collected for both groups. Covariates 
were analyzed using conditional logistic regression. Classification and regression tree analysis was used 
to identify the ME dose associated with QTc prolongation. 
Results: Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 
3.7–38.2; p < 0.00), peptic ulcer disease (PUD) (odds ratio [OR]: 8.3; 95% confidence interval [95% CI]: 
2.4–28.9; p < 0.00), hypokalemia (OR: 6.5; 95% CI: 1.5–28.2; p < 0.01), rheumatologic diseases (OR: 4.7; 
95% CI: 1.6–13.9; p < 0.00), taking medications with a known torsades de pointes (TdP) risk (OR: 4.4; 95% 
CI: 1.8–10.7; p < 0.01), malignancy (OR: 3.3; 95% CI: 1.2–9.3; p < 0.03), hypocalcemia (OR: 2.1; 95% CI: 
0.9–4.8; p < 0.07), and ME doses >45 mg per day (OR: 1.9; 95% CI: 0.8–4.8; p < 0.16). Mild liver disease 
was protective against QTc prolongation (OR: 0.05; 95% CI: 0.0–0.46; p < 0.01). 
Conclusions: Predictors of QTc prolongation in our multivariate conditional logistic regression model 
included CHF, PUD, hypokalemia, rheumatologic disorders, use of medications with a known TdP risk, 
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Abstract: 
Background:  Methadone (ME) is commonly used in pain and palliative care (PPC) patients with 
refractory pain or intolerable opioid adverse effects (AEs).  A unique ME AE is its QTc interval 
prolongation risk but most evidence exists in methadone maintenance therapy) patients.   
Objective:  Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME 
and other medications known to prolong the QTc interval and develop a risk stratification tool. 
Design:  We performed a case control study of adult inpatients receiving ME for pain management.    
Settings/Subjects:  Adult inpatients receiving ME with a QTc > 470 msec (males) and > 480 msec 
(females) were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients 
who did not have a prolonged QTc interval.    
Measurements:  QTc prolongation risk factors were collected for both groups.   Covariates were 
analyzed using conditional logistic regression.  Classification and regression tree analysis was used to 
identify the ME dose associated with QTc prolongation.    
Results:  Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 
3.7-38.2; p<0.00), peptic ulcer disease (PUD) (OR: 8.3; 95% CI: 2.4-28.9; p<0.00), hypokalemia (OR: 
6.5; 95% CI: 1.5-28.2; p<0.01), rheumatologic diseases (OR: 4.7; 95% CI: 1.6-13.9; p<0.00), taking 
medications with a known torsades de pointes risk (OR: 4.4; 95% CI: 1.8-10.7; p<0.01), malignancy (OR: 
3.3; 95% CI: 1.2-9.3; p<0.03), hypocalcemia (OR: 2.1; 95% CI: 0.9-4.8; p<0.07), and ME doses > 
45mg/day (OR: 1.9; 95% CI: 0.8-4.8; p<0.16).  Mild liver disease was protective against QTc 
prolongation (OR: 0.05; 95% CI: 0.0-0.46; p<0.01).   
Conclusion:  Predictors of QTc prolongation in our multivariate conditional logistic regression model  
included CHF, PUD, hypokalemia, rheumatologic disorders, use of medications with a known TdP risk, 
malignancy, hypocalcemia, and ME doses > 45mg/day.   
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Introduction:   
Methadone is a synthetic opioid that is a µ and δ receptor agonist, N-methyl-D-aspartate (NDMA) 
receptor antagonist, and inhibits reuptake of serotonin and norepinephrine.1-4   Its use for pain and 
palliative care (PPC) patients who have a poor response to previous opioid regimens or experience 
intolerable opioid adverse effects has increased methadone’s prescribing frequency.  A unique methadone 
adverse effect (AE) compared to other opioid agonists is its risk of prolonging the corrected QT (QTc) 
interval which serves as a surrogate marker for predicting torsades de pointes (TdP) or sudden cardiac 
death.5   Since 2000 methadone is the second most commonly reported drug causing QTc prolongation or 
TdP in the US Food and Drug Administration Adverse Event Reporting System (FDA AERS).6  
However, most of the evidence for methadone induced QTc prolongation is in methadone maintenance 
therapy (MMT) patients, not chronic pain or more medically fragile palliative care patients.  The risk of 
QTc prolongation is increased in patients with electrolyte disturbances, structural heart disease, 
bradycardia, female sex, advanced age, a history of QTc prolongation, concurrent use of other QTc 
prolonging medications, and drug interactions that increase serum concentrations of QTc prolonging 
drugs.7  The majority of drug-induced QTc prolongation cases occur when patients have at least one 
additional risk factor.8  It is common practice for palliative care and chronic pain patients to have several 
risk factors, especially the use of multiple drugs known to prolong QTc or decrease methadone clearance.  
A limitation in the current literature is the dearth of studies assessing the additive effect of QTc 
prolongation from the use of multiple QTc prolonging medications and/or drugs that inhibit methadone 
metabolism on QTc prolongation.  This lack of understanding about the potential clinical harms when 
methadone is combined with interacting medications was identified as a research gap in a recent review.9  
Our goal was to identify QTc interval prolongation risk factors in palliative care and chronic pain patients 
receiving methadone and other drugs known to prolong the QTc interval and/or inhibit methadone 
metabolism in order to develop a risk stratification tool to estimate this risk in this patient population. 
Methods: 
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Patients: 
This was a case-control study.  Potential subjects were identified through pharmacy records at the 
University of Rochester Medical Center’s (URMC) Strong Memorial and Highland Hospitals between 
March 14, 2011 and March 14, 2014.   Adult inpatients who received methadone for at least one week 
prior to hospitalization and had an EKG obtained within 2 weeks prior to admission or during the first 24 
hours after hospital admission were included. Patients receiving MMT for substance abuse, admitted as a 
hospice encounter, age < 18 years, or had incomplete medical records were excluded.  ECGs included 
within the patient's electronic medical record were used to determine the presence or absence of QTc 
interval prolongation. All ECGs were previously reviewed by an attending cardiologist for accuracy. QTc 
is calculated at URMC using Bazett’s correction formula.10   QTc interval prolongation was defined as 
QTc interval > 470 msec (males) and > 480 msec (females) or a QTc interval increase > 60 msec from 
baseline following the definitions from the American Heart Association/American College of Cardiology 
Foundation (AHA/ACCF) and Food and Drug Administration (FDA).11,12  The AHA/ACCF definition 
was selected because it differentiates between genders.  The FDA definition of a > 60 msec increase was 
chosen since it represents a more clinically significant change than > 30 msec.   
Patients with a prolonged QTc interval were designated as cases whereas those without QTc interval 
prolongation were classified as controls.  Cases and controls were matched 1:2 according to age range by 
decade, gender, and history of QTc prolongation.   
Procedures: 
The following data was obtained from each patient’s medical records: age, sex, comorbidities, history of 
QTc interval prolongation, baseline QTc interval and uncorrected QT interval, heart rate at time of 
baseline QT/QTc interval, history of structural heart disease (e.g. myocardial infarction, heart failure, 
valvular disease, or cardiomyopathy), history of bradycardia, history of conduction disorders (e.g. bundle 
branch block, heart block, arrhythmias, syncope, or long Q-T syndrome), electrolyte abnormalities at the 
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time of initial inpatient labs (e.g. hypokalemia, hypomagnesemia, or hypocalcemia).7  Hypokalemia was 
defined as K+ < 3.3 mEq/L, hypomagnesemia as Mg2+ < 1.3 mEq/L, and hypocalcemia delineated as a 
corrected Ca2+ < 8.8 mg/dL based on our health system’s laboratory reference range. The Charlson 
Comorbidity Index was used to calculate comorbidity scores.13  Concurrent use of other QTc-prolonging 
medications as classified by CredibleMeds.org was collected.14  This website categorizes medications into 
four classes based on TdP risk (e.g. medications with a known risk of TdP, possible risk of TdP, 
conditional risk of TdP, and drugs to avoid in congenital long QT).  Use of medications that increase 
serum methadone concentrations such as but not limited to fluconazole, fluoxetine, paroxetine, sertraline, 
ciprofloxacin, amitriptyline, desipramine, voriconazole were included.15,16  Methadone indication, 
scheduled dose, route, frequency, and duration of use at the time of inpatient admission was obtained.  
Breakthrough methadone doses were not included in the methadone daily dose calculations.  One 
investigator evaluated all the electronic medical records and collected patient data.  The study was 
approved by the URMC institutional review board, and the requirement for informed consent was waived. 
Statistical Analyses: 
Assuming a prior methadone exposure of 40% in controls, we calculated a sample size of 90 case patients 
and 180 controls (ratio, 1:2) for the study to have an 80% chance of detecting a clinically meaningful 
odds ratio of 2.5 between the two groups at the 5% significance level.  This was deemed to be clinically 
significant and necessitate a medication regimen adjustment.  We compared the odds of case patients and 
controls through conditional logistic regression to account for the matching design.  Demographic and 
baseline clinical characteristics between case patients and matched controls were compared using paired 
t-tests for continuous variables and McNemar’s chi-square tests for categorical variables. Variables with a 
p-value < 0.2 identified in the bivariate analysis were considered as potential confounders in a 
multivariable conditional logistic regression, using backward and forward stepping.  We obtained an 
adjusted estimate of QTc prolongation by adjusting for covariables that significantly improved the 
likelihood of the model.  Classification and regression tree analysis (CART) was used to identify the 
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methadone dose associated with QTc prolongation.  All reported P values and 95% confidence intervals 
were two-sided.  A P value of less than 0.05 was considered to indicate statistical significance.  STATA, 
version 13.1 (College Station, TX) was used for analyses. 
Results: 
A total of 908 patients were screened for this study (Figure 1).  Two hundred ninety-nine patients were 
immediately excluded for the following reasons: 190 patients on MMT, 84 patients did not have a 
documented ECG, and 25 patients were < 18 years.  Three hundred ninety-one did not have a prolonged 
QTc interval, of which 180 patients were included as controls, and 211 patients were excluded for reasons 
outlined in Figure 1.  Two hundred eighteen patients had a prolonged QTc interval.  Ninety patients were 
classified as controls, 103 patients were identified with a prolonged QTc interval while matching case 
controls and 25 patients did not meet inclusion criteria as detailed in Figure 1. 
Table 1 outlines patient demographics.  Case patients had a median age of 55 years compared to controls 
whose median age was 57 years.  No case or controls had a previous history of QTc prolongation.  
Among case and control patients 56.7% were female and 43.3% were male.  The mean total Charlson 
comorbidity score was 4.9 (SD: 3.2) for cases and 4 (SD: 3.1) in controls.   Among cases, methadone was 
indicated for chronic pain in 69 patients (76.7%), cancer pain in 19 patients (21.1%), and chronic and 
cancer pain in 2 patients (2.2%).  One hundred-fifteen control patients (63.9%) received methadone for 
chronic pain compared to 52 patients (28.9%) for cancer pain, and chronic and cancer pain in 13 patients 
(7.2%).   The median ME dose was 36.3mg (SD: 27.7mg) in cases (range: 5mg-120mg/day) and 34.6mg 
(SD: 29.9mg) among controls (range:  5-240mg/day).  Cases used ME for a median of 199 days (SD: 
302.9 days) prior to study entry and 197 days (SD: 318.3 days) for controls.   
Table 2 lists the variables from the univariate analysis included in the conditional multivariate logistic 
regression model.  The final model was tested for collinearity, statistical interactions, and confounding 
variables.  The results of our conditional multivariate logistic regression analysis are included in Table 3.  
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The most significant variables to predict QTc prolongation in our multivariate conditional logistic 
regression model were congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7-38.2; p<0.00), peptic ulcer 
disease (PUD) (OR: 8.3; 95% CI: 2.4-28.9; p<0.00), hypokalemia (OR: 6.5; 95% CI: 1.5-28.2; p<0.01), 
rheumatologic diseases (OR: 4.7, 95%: 1.6-13.9; p<0.00), concurrent use of medications with known TdP 
risk (OR: 4.4; 95% CI: 1.8-10.7; p<0.01), malignancy (OR: 3.3; 95% CI: 1.2-9.3; p<0.03), hypocalemia 
(OR: 2.1; 95% CI: 0.9-4.8; p<0.07), and ME doses > 45mg/day (OR: 1.9; 95% CI: 0.8-4.8; p<0.16).  Mild 
liver disease decreased patient’s QTc prolongation risk (OR: 0.05, 95% CI:  0.0-0.46; p<0.01).          
Discussion: 
We identified 6 studies in the literature that evaluated methadone’s effect on QTc prolongation in PPC 
patients.17-22  Three studies identified other risk factors that contributed to ME induced QTc 
prolongation17,18,20  Price et al identified increased risk of cardiac events (composite endpoint: QTc > 500 
msec, cardiac death, or hospitalization/emergency department visit for a cardiac etiology) in 1246 primary 
care chronic pain patients with oral ME doses > 100mg/day (OR: 6.18; 95% CI: 1.08-35.45) and 
increasing age (OR: 1.06; 95% CI: 1.03-1.09).17  Female gender (p=0.0061) and antidepressant use 
(p=0.0397) were identified as risk factors for a prolonged QTc interval ( >450msec) in 90 chronic pain 
outpatients taking ME compared to controls without ME exposure.18  Concurrent use of medications 
associated with QTc prolongation risk, structural heart disease, electrolyte abnormalities, and female 
gender were found to increase QTc prolongation risk (QTc interval increase >25% from baseline or 
>500msec) in 100 palliative care patients receiving ME for cancer pain.20   These studies utilized different 
definitions of QTc interval prolongation, so clinical judgement should be utilized when interpreting 
findings.   
Our final multivariate logistic regression model identified CHF, PUD, hypokalemia, rheumatologic 
diseases, medications with a known TdP risk, malignancy, hypocalcemia, and ME doses > 45mg/day as 
potential risk factors and mild liver disease had a protective effect against QTc prolongation in our 
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chronic pain and palliative care patients.  Methadone is most commonly prescribed by a limited number 
of specialists within our health system who care for PPC patients.  Our findings may be influenced by 
local prescribing patterns and the risk factors we identified in our study may slightly vary when compared 
to those identified for PPC patients in other geographic areas.  The URMC palliative care service 
frequently collaborates with our institution’s advanced heart failure  and oncology programs.  The large 
heart failure  and oncology programs in our health system may account for the large number of patients 
with these risk factors in our model.  Thirty-two case patients had heart failure  compared to 19 control 
patients and malignancy occurred in 22 case patients versus 18 control patients.  Heart failure  and 
hypokalemia are closely related risk factors given the frequent use of loop diuretics in this patient 
population and were also identified along with hypocalcemia as risk factors by Reddy et al.20  
Rheumatologic diseases were likely a risk factor because lupus nephritis is a common systemic lupus 
erythematous (SLE) complication and methadone is a preferred opioid in renal insufficiency.23   PUD was 
an unexpected risk factor. Multiple variables may have contributed to this finding, including the potential 
for increased use of opioids vs. NSAIDs for pain management with this comorbidity or through increased 
exposure to methadone via inhibition of CYP2C19 with concurrent use of PPIs.24    
It was expected that concomitant use of medications with a known TdP risk would have an additive effect 
on QTc prolongation risk given the frequent use of antipsychotics, antiemetics, and antidepressants for 
mental health comorbidities and symptom management in PPC patients.  This was consistent with Reddy 
et al. findings.20  We did not assess the impact of dose, actual as needed (e.g. prn) medication utilization, 
or route of administration in our risk assessment of other QTc prolonging medications.  Differences in 
these risk variables may pose a higher QTc prolongation risk when comparing medication doses or 
selected routes of administration.  For example, 6mg of intravenous haloperiodol has a higher QTc 
prolongation risk than 2mg of oral haloperidol.  Our model did not account for concurrent use of multiple 
QTc prolonging medications within the same risk class.  A patient taking three medications with a known 
risk of TdP in addition to methadone likely has a higher risk of QTc prolongation than a subject taking 
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methadone and one medication with a known risk of TdP. Methadone doses > 45mg/day were identified 
to increase QTc prolongation risk in our model.  This dose is lower than the > 100mg/day dose that was 
identified by Price et al. to increase cardiac event risk.  It is unclear why mild liver disease decreased QTc 
prolongation risk in our study cohort.  Hypokalemia, hypocalcemia, concurrent use of medications with 
known TdP risk, and ME doses > 45mg/day are potentially modifiable risks factors.  Providers caring for 
PPC patients should correct or minimize these modifiable risk factors when clinically feasible.  Heart 
failure, PUD, and rheumatologic diseases are less modifiable risk factors in PPC patients given the 
frequency of advanced stages of chronic illnesses and limited life expectancy in this population.    
This study has several additional limitations which may have impacted our findings.  Despite having one 
investigator collect and code all the data, there is still a potential for incomplete or miscoded data.  Since 
many study patients were on ME prior to our health system’s electronic medical record implementation or 
were initiated on methadone by a provider outside of our health system, we did not consistently have 
baseline ECGs or methadone start dates available for all patients.  Bazett’s correction formula is not as 
accurate as the Fridericia’s correction formula for tachycardic and bradycardic patients.12  We utilized the 
Bazett’s correction formula for all study patients which likely resulted in an overcorrected QTc interval in 
tachycardic patients and an undercorrected QTc interval with bradycardic patients.  The small sample size 
made it difficult to compare various risk factors such as valvular heart disease due to low frequency of 
occurrence.  Cardiac arrest and use of cardioversion were not included in our data collection since many 
of our palliative care patients had do not resuscitate (DNR) orders.    
One variable that we did not assess was the impact of pharmacogenomics.  Findings from the 
MEMORIES trial demonstrated that MMT patients with a CYP2C19*2 gene variant had higher plasma 
concentrations of methadone’s primary metabolite, ethylidene-1, 5-dimethyl-3,3-diphenylpyrrolidene 
(EDDP) than subjects with the wild type gene (p<0.004).25  Elevated EDDP levels produced a non-
statistically significant increase in the QTc interval from baseline (p=0.1).  This pilot study draws 
attention to the potential influence of CYP2C19 variants on methadone induced QTc interval lengthening.       
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Our study included a heterogeneous patient cohort of chronic pain and palliative care patients.  There are 
advantages and disadvantages of combining these two patient populations.  Palliative care patients often 
have a shorter life expectancy and more severe symptoms making providers more accepting of a longer 
QTc interval or less likely to aggressively correct modifiable risk factors because the benefit of 
methadone for treating refractory pain outweighs the risk of developing TdP.  Chronic pain patients have 
a longer life expectancy, so there is a lower threshold to modify risk factors that increase the QTc interval.  
However chronic pain and palliative care patient populations are more similar than those in studies that 
included both chronic pain and MMT patients.  This improves the external validity of our findings when 
assessing which QTc prolongation risk factors are most clinically significant to chronic pain and palliative 
care patients.       
Conclusions: 
Predictors of QTc prolongation in our multivariate conditional logistic regression model of this PPC 
patient cohort included CHF, PUD, hypokalemia, rheumatologic disorders, concurrent use of medications 
with a known TdP risk, malignancy, hypocalcemia, and ME doses > 45mg/day.  PPC patients with these 
risk factors are at increased risk of developing a prolonged QTc interval while taking methadone.  
Clinicians caring for these patients should minimize exposure to the identified risk factors and correct 
modifiable risk factors when clinically feasible.  Additional population based studies are needed in larger, 
more diverse PPC patient cohorts to support these findings.          
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Table 1. Patient Demographics 
Characteristic 
Cases  
n = 90 (%) 
Controls 
n = 180 (%) 
   
Age, y; Median  55 57 
Females 51 (56.7) 102 (56.7) 
Total Charlson Comorbidity   
     Score, Mean (SD) 4.9 (3.2) 4.0 (3.1) 
Methadone Indication:    
     Chronic Pain 69 (76.7) 115 (63.9) 
     Cancer Pain 19 (21.1) 52 (28.9) 
     Chronic and Cancer Pain 2 (2.2) 13 (7.2) 
Methadone Rt of Admin:   
      Oral 86 (95.6) 170 (94.4) 
      Feeding Tube (PEG, J-tube) 4 (4.4) 10 (5.6) 
Total Oral Methadone Equivalent   
     Dose (mg), Mean (SD) 36.3 (27.7) 34.6 (29.9) 
Duration of Methadone Use    





   
 









Age, y; Median  55 57 1.1 (0.9 – 1.2) 0.18 
Females 51 (56.7%) 102 (56.7%) 1 (0.6 – 1.7) 1.00 
Total Charlson Comorbidity   
     Score, Mean (SD) 4.9 (3.2) 4.0 (3.1) 
 
0.03 1.1 (1.0 – 1.2) 
Comorbidity      
     Myocardial Infarction  7 (7.9) 9 (5) 1.6 (0.6 – 4.2) 0.38 
     Congestive Heart Failure 32 (35.6) 19 (10.6) 4.9 (2.4 – 9.8) 0.00 
     Peripheral Vascular Disease 6 (6.7) 13 (7.2) 0.9 (0.3 – 2.5) 0.87 
     CVD 12 (14.4) 24 (13.3) 1.1 (0.5 – 2.2) 0.81 
     Dementia  3 (3.3) 4 (2.2) 1.5 (0.3 – 6.7) 0.59 
     Chronic Pulmonary Disease 33 (36.7) 63 (35) 1.1 (0.6 – 1.9) 0.78 
     Rheumatologic Disorders  26 (28.9) 17 (9.4) 4.6 (2.1 – 9.9) 0.00 
     Peptic Ulcer Disease  28 (31.1) 11 (6.1) 11.5 (4.0 –33.1) 0.00 
     Mild Liver Disease  2 (2.2) 16 (8.9) 0.2 (0.05 – 1.0) 0.05 
     Diabetes Mellitus  17 (18.9) 37 (20.6) 0.9 (0.5 – 1.7) 0.73 
     Complications of DM 12 (13.3) 12 (6.7) 2.1 (0.9 – 4.7) 0.08 
     Plegia 3 (3.3) 9 (5) 0.7 (0.2 – 2.5) 0.54 
     Renal disease  31 (34.4) 40 (22.2) 1.8 (1.0 – 3.2) 0.04 
     Malignancy  22 (24.4) 18 (10) 2.8 (1.4 – 5.5) 0.00 
     Moderate/Severe Liver Dz 11 (12.2) 1 (0.6) 22 (2.8 – 170.4) 0.00 
     Metastasis – Solid Organ 15 (16.7) 52 (28.9) 0.5 (0.2 – 0.9) 0.03 
     AIDS 2 (2.2) 7 (3.9) 0.6 (0.1 – 2.8) 0.49 
Uncorrected QT Interval, ms 
     Median (SD) 408 (46.3) 372 (46.5) 
 
1.0 (1.0 – 1.0) 0.00 
History of Structural Heart Dz:      
     Myocardial Infarction  8 (8.9) 8 (4.4) 2 (0.8 – 5.3) 0.17 
     Heart Failure  32 (35.6) 19 (10.6) 4.9 (2.4 – 9.8) 0.00 
     Valvular Heart Disease  2 (2.2) 4 (2.2) 1 (0.2 – 5.5) 1.00 
     Atrial Septal Defect 1 (1.1) --- --- --- 
     Coronary Artery Disease  18 (20) 21 (11.7) 2.3 (1.0 – 5.1) 0.04 
     ECG Right or Left    
          Ventricular Hypertrophy  19 (21.1) 26 (14.4) 
 
1.6 (0.8 – 3.2) 0.16 
History of Conduction Disorders 18 (20) 24 (13.3) 1.6 (0.8 – 3.2) 0.74 
History of ECG Disorders  12 (13.3) 33 (18.3) 0.7 (0.3 – 1.4) 0.30 
History of Bradycardia 2 (2.2) 12 (6.7) 0.3 (0.1 – 1.4) 0.14 
Electrolytes:      
     Hypocalcemia 42 (46.7) 58 (32.2) 1.8 (1.1 – 3.1) 0.02 
     Hypokalemia  12 (13.3) 8 (4.4) 3.2 (1.3 – 8.3) 0.01 
     Hypomagnesemia 5 (5.6) 7 (3.9) 1.4 (0.5 – 4.5) 0.52 
Methadone Inhibitors:  25 (27.8) 29 (16.1) 1.9 (1.1 – 3.5) 0.03 
Duration of Methadone Use,    




197 (318.3) 1.0 (0.9 – 1.1) 
 
0.81 
Frequency of QTc Prolonging    
     Medications:    
 
          Zero 6 (6.7) 26 (14.4) Referent Referent 
          1 – 2  35 (38.9) 100 (55.6) 1.7 (0.6 – 4.8) 0.32 
          3 – 4        37 (41.1)        46 (25.6)      4.5 (1.5 – 13.0)                0.01 
          5 – 6        8 (8.9)        8 (8.9)      6.8 (1.6 – 30.0)                   0.01 
          > 6       4 (4.4)                          ---              ---                             --- 
Concomitant Medication with:    








     Possible Risk of TdP 39 (43.3) 78 (43.3)  1.00 
     Conditional Risk of TdP 59 (65.6) 95 (52.7)  0.04 
     Drug to Avoid in Long QT 37 (41.1) 44 (24.4)  0.00 
Methadone CART Analysis:            
     > 45 mg/day 31 (34.4) 44 (24.4) 1.7 (0.9 – 3.1) 
 
0.07 
TdP: torsades de pointes; CART:  classification and regression tree analysis;  Dz:  disease;  DM:  diabetes 
mellitus; OR:  odds ratio;  95% CI: 95% confidence interval 
Table 3.  Cases and Controls Multivariate Analysis Results  
Characteristic OR 95% CI p 
Hypokalemia  6.5 1.5 – 28.2 0.01 
Concomitant Medication with:    
     Known Risk of TdP  4.4 1.8 – 10.7  0.01 
Comorbidity:     
     Congestive Heart Failure  11.9 3.7 – 38.2 0.00 
     Rheumatologic Diseases  4.7 1.6 – 13.9  0.00 
     Peptic Ulcer Disease  8.3 2.4 – 28.9 0.00 
     Malignancy  3.3 1.2 – 9.3 0.03 
Hypocalcemia  2.1 0.9 – 4.8 0.07 
Mild Liver Disease  0.05 0.0 – 0.46 0.01 
ME CART Analysis (> 45mg/day) 1.9 0.8 – 4.8 0.16 
OR = Odds Ratio; CI = Confidence Interval 
 
 
 

